2018
DOI: 10.1007/s10096-018-3419-z
|View full text |Cite
|
Sign up to set email alerts
|

Management of adult Clostridium difficile digestive contaminations: a literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
11
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 142 publications
0
11
0
Order By: Relevance
“…On the other hand, capsules have major advantages compared to all the other options. Numerous studies (Vigvari et al, 2014;Mathias et al, 2019) have already proven the superiority of FMT to metronidazole and vancomycin, while other studies (Madoff Since capsule FMT has results that are similar to conventional FMT methods, these statements apply to our new protocol as well. A major advantage of capsule FMT to conventional FMT is the significantly lower volume: while 100 mL of faecal solution has to be administered through a nasogastric or nasojejunal tube, the same effect can be achieved with 4-7 capsules (depending on capsule type).…”
Section: Discussionmentioning
confidence: 66%
“…On the other hand, capsules have major advantages compared to all the other options. Numerous studies (Vigvari et al, 2014;Mathias et al, 2019) have already proven the superiority of FMT to metronidazole and vancomycin, while other studies (Madoff Since capsule FMT has results that are similar to conventional FMT methods, these statements apply to our new protocol as well. A major advantage of capsule FMT to conventional FMT is the significantly lower volume: while 100 mL of faecal solution has to be administered through a nasogastric or nasojejunal tube, the same effect can be achieved with 4-7 capsules (depending on capsule type).…”
Section: Discussionmentioning
confidence: 66%
“…After long antibiotic treatments, the normal microbiota is damaged, and the spores of C. difficile , that are in virtually all healthy human, can germinate fast, releasing toxins and producing the infection. The ability of C. difficile spores to escape the biocidal action of the antibiotics used for its treatment produces relapses in the disease and recurrence (Mathias et al, 2019; Song and Kim, 2019).…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, these antibiotics do not affect spores, and for this reason, the treatments have to be administered for a prolonged time. Antibiotics also lead to the disruption of the gut microbiota because of their low specificity, allowing the pathogen to proliferate and colonize the human gut after the treatment (Mathias et al, 2019). Moreover, the misuse of antibiotics has a central role in the emergence of novel and more virulent strains, characterized by higher antibiotic resistance and toxin production (Yakob et al, 2015; Candel-Pérez et al, 2019; Fatima and Aziz, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…This potentially substantial increase may be explained by the number of elderly patients, antibiotic consumption, the development of resistance to conventional antibiotics (eg, metronidazole, vancomycin, and fidaxomicin), and the emergence of hypervirulent strains. [2][3][4] The major problem with CDI is that despite adequate antibiotic therapy, 10%-30% of patients will experience a recurrence, with the risk approaching 60% after the third episode. 5 Fecal microbiota transplantation (FMT) is an effective therapy for CDI, leading to a significant reduction of recurrent Clostridium difficile infection (rCDI) and reduced incidence of adverse events when compared to conventional antibiotics (eg, vancomycin and fidaxomicin).…”
mentioning
confidence: 99%
“…5 Fecal microbiota transplantation (FMT) is an effective therapy for CDI, leading to a significant reduction of recurrent Clostridium difficile infection (rCDI) and reduced incidence of adverse events when compared to conventional antibiotics (eg, vancomycin and fidaxomicin). 4,[6][7][8] FMT is currently recommended by both European and American guidelines for multiple rCDI. 9,10 Other indications of FMT are being studied, such as inflammatory bowel diseases (IBDs; eg, ulcerative colitis and Crohn's disease), obesity, type 2 diabetes, or graft-versus-host disease.…”
mentioning
confidence: 99%